Trisomy 8 Defines a Distinct Subtype of Myeloproliferative Neoplasms Driven by the MYC–Alarmin Axis
Authors:
- Nicole D. VinceletteNVNicole D. Vincelette
- Xiaoqing YuXYXiaoqing Yu
- Andrew T. KuykendallAKAndrew T. Kuykendall
- Jungwon MoonJMJungwon Moon
- Siyuan SuSSSiyuan Su
- Chia-Ho ChengCCChia-Ho Cheng
- Rinzine SammutRSRinzine Sammut
- Tiffany N. RazabdouskiTRTiffany N. Razabdouski
- Hai V. NguyenHNHai V. Nguyen
- Erika A. EksiogluErika A. Eksioglu
- Onyee ChanOCOnyee Chan
- Najla Al AliNANajla Al Ali
- 7 May 2024
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 5 (4) , 276-297
Abstract
Despite advances in understanding the genetic abnormalities in myeloproliferative neoplasms (MPN) and the development of JAK2 inhibitors, there is an urgent need to devise new treatment strategies, particularly for patients with triple-negative (TN) myelofibrosis (MF) who lack mutations in the JAK2 kinase pathway and have very poor clinical outcomes. Here we report that MYC copy number gain and increased MYC expression frequently occur in TN-MF and that MYC-directed activation of S100A9, an alarmin protein that plays pivotal roles in inflammation and innate immunity, is necessary and sufficient to drive development and progression of MF. Notably, the MYC-S100A9 circuit provokes a complex network of inflammatory signaling that involves numerous hematopoietic cell types in the bone marrow microenvironment. Accordingly, genetic ablation of S100A9 or treatment with small molecules targeting the MYC-S100A9 pathway effectively ameliorates MF phenotypes, highlighting the MYC–alarmin axis as a novel therapeutic vulnerability for this subgroup of MPNs. Significance: This study establishes that MYC expression is increased in TN-MPNs via trisomy 8, that a MYC-S100A9 circuit manifest in these cases is sufficient to provoke myelofibrosis and inflammation in diverse hematopoietic cell types in the BM niche, and that the MYC-S100A9 circuit is targetable in TN-MPNs.Keywords
All Related Versions
Funding Information
- American Society of Clinical Oncology
- American Society of Hematology
- National Health and Medical Research Council (1016701)
- Deutsche Krebshilfe (109220)
- National Cancer Institute (K08 CA237627)
- National Cancer Institute (R50 CA211447-06A1)
- National Cancer Institute (P30-CA076292)
- National Cancer Institute (R01 CA280116)
This publication has 66 references indexed in Scilit:
- Early and late stage MPN patients show distinct gene expression profiles in CD34+ cellsAnnals of Hematology, 2021
- Macrophage frequency in the bone marrow correlates with morphologic subtype of myeloproliferative neoplasmAnnals of Hematology, 2020
- Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance ImmunotherapyCancer Cell, 2019
- Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With MyelofibrosisJAMA Oncology, 2018
- Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative NeoplasmsCancer Cell, 2018
- Safety and Efficacy of Fedratinib in Patients With Primary or Secondary MyelofibrosisJAMA Oncology, 2015
- MYC on the Path to CancerCell, 2012
- CD4+ T Cells Contribute to the Remodeling of the Microenvironment Required for Sustained Tumor Regression upon Oncogene InactivationCancer Cell, 2010
- Physiological Jak2V617F Expression Causes a Lethal Myeloproliferative Neoplasm with Differential Effects on Hematopoietic Stem and Progenitor CellsCancer Cell, 2010
- Cytogenetic features in myelodysplastic syndromesAnnals of Hematology, 2008